(Total Views: 765)
Posted On: 11/12/2017 3:47:37 PM
Post# of 102
Nutra Pharma NPHC undervalued phase II news will send it. No R/S
400,000 debt reduced
http://www.otcmarkets.com/edgar/GetFilingHtml...D=12359349
Website: http://www.nutrapharma.com
Phone: (954) 509-0911
Email: investor.relations@nutrapharma.com
21 Patents
400,000 debt reduced
http://www.otcmarkets.com/edgar/GetFilingHtml...D=12359349
Quote:
Email from Rik (Great things on the horizon)
CEO UPDATE: NPHC
We need to file our 10Q next week. After that, we can announce our ‘go-forward’
plans for the company. This includes: the ongoing infomercial campaign for Pet
Pain-Away; the marketing of Nyloxin; the retail rollout for Nyloxin; the ongoing
efforts to get our products into the VA and government buyers; our efforts in
International registrations for our products; and our efforts in moving RPI-78M
into clinical trials for Pediatric Multiple Sclerosis under our Orphan Designation.
We are working with finance partners and potential joint venture partners to bring
in from $2M to $20M in furtherance of the business plan. We expect to make
announcements later this month to update our shareholders.
Thank you for your interest in Nutra Pharma,
Rik
Post from 'tink/hub'
Website: http://www.nutrapharma.com
Phone: (954) 509-0911
Email: investor.relations@nutrapharma.com
21 Patents
(1)
(0)
[img]montrealgotstyle.com/wp-content/uploads/2017/09/pker.gif[/img]
HPMM PCLI ZMRK OXIHF IKTO VGLS RMRK APRU NWPN SNRY MEDH
HPMM PCLI ZMRK OXIHF IKTO VGLS RMRK APRU NWPN SNRY MEDH
Scroll down for more posts ▼